You are here: Industry Insights > Novo Nordisk

News List

Novo Nordisk results show GLP-1s are job 1. Can its crucial Ozempic launch deliver? fiercepharma
May 03, 2018
After Eli Lilly reported street-beating diabetes sales in the first quarter while Sanofi’s suffered, all eyes were turned to Novo Nordisk.
Sempre Health and Novo Nordisk Partner to Improve Medication Costs for Patients With Diabetes biospace
April 19, 2018
Sempre Healthtoday announced it's collaborating on a pilot program with Novo Nordiskto add diabetes medications to the Sempre Health affordability & engagement solution.
Novo Nordisk launches Rebinyn, a new, long-acting treatment for patients with hemophilia B in Canada biospace
April 12, 2018
Novo Nordisk announced the launch and availability of Rebinyn® (Coagulation Factor IX (Recombinant), pegylated)
Novo Nordisk Ties Up Sickle Cell Disease Treatment in $400M Deal biospace
April 08, 2018
Danish pharma giant Novo Nordisk tied up a sickle cell and beta-thalassemia program in a $400 million deal with Ohio-based EpiDestiny.
Semaglutide injection phase 2 data presented at ENDO demonstrated significant weight loss in adults biospace
March 20, 2018
An oral presentation of data from this trial investigating the safety and efficacy of semaglutide as a potential treatment for adults with obesity took place at the Endocrine Society's annual meeting in Chicago (ENDO).
Novo Nordisk’s diabetes pill presents the first successful data biospectrumasia
February 27, 2018
The oral form of the drug, known generically as semaglutide, is crucial for ensuring the group's long-term growth, as price pressure mounts in a crowded market targeting the world's 450 million diabetics.
Novo Nordisk and Eskayef unite to manufacture modern insulin biospectrumasia
February 02, 2018
Transfer of Novo Nordisk's proprietary technology to Eskayef for the production of human and modern insulin cartridges to Bangladesh
Novo Nordisk has proposed to acquire Ablynx biospectrumasia
January 10, 2018
Novo Nordisk recently announced that it made a proposal on 22 December 2017 to acquire Ablynx for EUR 28.00 per share in cash and one CVR with total potential cash payments over time of up to EUR 2.50 per share.
Rejected Again: Ablynx Turns Down Novo Nordisk's Sweetened $3.1B Bid biospace
January 09, 2018
Novo Nordisk A/S has twice made a bid to acquire Ablynx NV., and twice been rejected. The first bid was on Dec. 7, 2017, for about $31.57 per share in cash.
Xultophy® shows significant results for type 2 diabetes patients in real-world setting pharmaasia
December 19, 2017
Xultophy® by Novo Nordisk has been shown to significantly reduced blood sugar levels in people with type 2 diabetes after six months.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 13 14 Next page